MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Dyskinesias"

  • 2018 International Congress

    Assessing the potential cost-effectiveness of ads-5102 (Amantadine HCl) for the treatment of dyskinesia in Parkinson’s disease patients

    R. Pahwa, L. Garrison, M. Zimmerman, R. Johnson, J. Nguyen, M. Li, R. Patni (Kansas City, KS, USA)

    Objective: This economic evaluation projects the likely cost-effectiveness of ADS-5102 in comparison to the current standard of best supportive care. Background: In August, 2017, the…
  • 2018 International Congress

    Neutrophil to lymphocyte ratio, lymphocyte to monocyte ratio and Parkinson’s Disease: Preliminary report

    B. Lisewska, P. Lisewski, P. Szarwas, N. Piekuś-Słomka, D. Rość (Bydgoszcz, Poland)

    Objective: We conducted a pilot study to determine the association between the neutrophil to lymphocyte ratio (NLR), he lymphocyte to monocyte ratio (LMR), the levels…
  • 2018 International Congress

    Mild to moderate dyskinesia is not significantly related to the level of activity engagement or quality of life of patients with Parkinson’s disease

    E. Goubault, S. Bogard, K. Lebel, C. Duval (Montréal, QC, Canada)

    Objective: This cross-sectional study aimed at determining the relation between levels of drug-induced dyskinesia (DID), tremor, rigidity, bradykinesia, postural instability, as well as cognition and…
  • 2018 International Congress

    Does motor laterality affect the development of dyskinesia in patients with Parkinson’s disease?

    S. Chung, H. Yoo, J. Oh, J. Kim, P. Lee, Y. Sohn (Seoul, Republic of Korea)

    Objective: To investigate the effects of motor laterality on the development of levodopa-induced dyskinesia (LID) in patients with de novo Parkinson’s disease (PD). Background: LID…
  • 2018 International Congress

    The scaling properties of chorea and levodopa-induced dyskinesia are similar to voluntary movements

    J. Daneault, C. Duval, J. Miranda (Newark, NJ, USA)

    Objective: Explore whether levodopa-induced dyskinesia (LID) and chorea share voluntary movement characteristics to better understand the mechanisms underlying these involuntary movements. Background: We have recently…
  • 2018 International Congress

    Prevalence and risk factor of peak-dose dyskinesia in Thai patients with Parkinson’s disease

    S. Klanbut, C. Luangsinsiri, N. Piyaparneekul, C. Khongbut, K. Methawasin (Nakhon Nayok, Thailand)

    Objective: To determine the prevalence and risk factors associated with peak-dose dyskinesia in Thai patients with Parkinson’s disease. Background: Dyskinesias are involuntary movement that interfere…
  • 2017 International Congress

    Impact of levodopa-induced dyskinesias on Health-related Quality of Life. Results from the French COPARK study.

    S. Perez-Lloret, L. Negre-Pages, P. Damier, A. Delval, P. Derkinderen, A. Destée, W. Meissner, F. Tison, O. Rascol (Buenos Aires, Argentina)

    Objective: To assess the impact of LIDs on HRQoL in this large sample of unselected Parkinson’s Disease (PD) patients and to assess the factors related…
  • 2017 International Congress

    Protocol for upper-limb kinematic analysis in paediatric movement disorders and relative normality data

    L. Garavaglia, E. Pagliano, A. Lo Mauro, G. Baranello, A. Aliverti, S. Pittaccio (Lecco, Italy)

    Objective: The study proposes a specialised protocol to collect and analyse kinematic data from paediatric patients affected by Movement Disorders (MD). The aim is to…
  • 2017 International Congress

    Factors associated with occurrence of motor complications among Parkinson’s disease patients with levodopa treatment in Estonia

    L. Kadastik-Eerme, N. Taba, T. Asser, P. Taba (Tartu, Estonia)

    Objective: To identify the factors associated with the occurrence of motor complications among patients with Parkinson’s disease (PD) who receive levodopa treatment. Background:  Levodopa is the…
  • 2017 International Congress

    How efficient is subthalamic deep brain stimulation in reducing dyskinesia in Parkinson’s Disease?

    N. Kovacs, A. Juhász, I. Balás (Pecs, Hungary)

    Objective: The aim of this study was to determine whether the UDysRS can detect improvement in dyskinesia reliably after bilateral subthalamic nucleus DBS for PD.…
  • « Previous Page
  • 1
  • …
  • 28
  • 29
  • 30
  • 31
  • 32
  • …
  • 40
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
    • #25062 (not found)
    • Welcome to the MDS Abstracts Site
    • Effect of marijuana on Essential Tremor: A case report
    • Advanced Search
    • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
    • Covid vaccine induced parkinsonism and cognitive dysfunction
    • Help & Support
    • About Us
    • Cookies & Privacy
    • Wiley Job Network
    • Terms & Conditions
    • Advertisers & Agents
    Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
    Wiley